Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Haplnscience Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner in 1 distinct art unit. ABBAS, SYED JARAR is the busiest examiner with 1 pending action. This single action constitutes the company's entire current pending prosecution profile. For a practitioner, this means the prosecution strategy is entirely focused on a single examiner's requirements.
The presence of 1 distinct art unit indicates a specific technical niche for the company's current biotechnology filing. Because there is only 1 distinct examiner involved, the legal team can focus exclusively on the preferences and past actions of ABBAS, SYED JARAR. There is no complexity arising from multiple art units or varying examiner styles. This 1 pending office action represents a streamlined prosecution path where the outcome is determined by a single examination process. The data shows a highly concentrated intellectual property focus, with no other active matters currently pending in the biotechnology and pharmaceutical sector for this company.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ABBAS, SYED JARAR | 1 | 25.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18725623 | COMPOSITION FOR PREVENTION OR TREATMENT OF DRY EYE DISEASE COMPRISING HAPLN1 | ABBAS, SYED JARAR | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18725623 | COMPOSITION FOR PREVENTION OR TREATMENT OF DRY EYE DISEASE COMPRISING HAPLN1 | ABBAS, SYED JARAR | 1674 | §103§112 | Non-Final OA | — | Pending | Jun 28, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHaplnscience Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Syed Jarar Abbas has the most, with 1 of Haplnscience Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
